N. Ortego

1.5k total citations
23 papers, 456 citations indexed

About

N. Ortego is a scholar working on Rheumatology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, N. Ortego has authored 23 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in N. Ortego's work include Systemic Lupus Erythematosus Research (7 papers), Ocular Diseases and Behçet’s Syndrome (5 papers) and Systemic Sclerosis and Related Diseases (4 papers). N. Ortego is often cited by papers focused on Systemic Lupus Erythematosus Research (7 papers), Ocular Diseases and Behçet’s Syndrome (5 papers) and Systemic Sclerosis and Related Diseases (4 papers). N. Ortego collaborates with scholars based in Spain, United States and Mexico. N. Ortego's co-authors include José Luís Callejas-Rubio, Ricardo Blanco, M. Díaz-Llopis, J.M. Benítez-del-Castillo, Gabriela Ortega, Carlos Marras, J.L. Olea, Alex Fonollosa, David Salom and J. Fernando Arévalo and has published in prestigious journals such as Ophthalmology, The Journal of Urology and Annals of the Rheumatic Diseases.

In The Last Decade

N. Ortego

19 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Ortego Spain 8 234 226 106 75 46 23 456
M. Frigui Tunisia 12 82 0.4× 202 0.9× 70 0.7× 76 1.0× 42 0.9× 41 349
A. Hamzaoui Tunisia 10 148 0.6× 130 0.6× 109 1.0× 54 0.7× 22 0.5× 54 339
Esen Kasapoğlu Günal Türkiye 10 208 0.9× 336 1.5× 79 0.7× 136 1.8× 30 0.7× 23 492
M. Khanfir Tunisia 15 339 1.4× 275 1.2× 151 1.4× 95 1.3× 24 0.5× 68 604
Ayten Yazıcı Türkiye 13 175 0.7× 233 1.0× 116 1.1× 98 1.3× 17 0.4× 87 496
A Sbaï France 14 157 0.7× 192 0.8× 156 1.5× 50 0.7× 45 1.0× 34 570
Hanns-Martin Lorenz Germany 10 162 0.7× 95 0.4× 205 1.9× 96 1.3× 45 1.0× 12 478
Olcay Aydıntuğ Türkiye 11 102 0.4× 231 1.0× 73 0.7× 95 1.3× 14 0.3× 20 426
V. Calvo-Río Spain 15 294 1.3× 428 1.9× 354 3.3× 60 0.8× 44 1.0× 42 725
Adam Adler United States 7 77 0.3× 102 0.5× 93 0.9× 112 1.5× 100 2.2× 10 381

Countries citing papers authored by N. Ortego

Since Specialization
Citations

This map shows the geographic impact of N. Ortego's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Ortego with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Ortego more than expected).

Fields of papers citing papers by N. Ortego

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Ortego. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Ortego. The network helps show where N. Ortego may publish in the future.

Co-authorship network of co-authors of N. Ortego

This figure shows the co-authorship network connecting the top 25 collaborators of N. Ortego. A scholar is included among the top collaborators of N. Ortego based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Ortego. N. Ortego is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zozaya, Néboa, I. Castellví, Jaime Espín, et al.. (2022). A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. International Journal of Technology Assessment in Health Care. 38(1). e64–e64. 2 indexed citations
2.
Saavedra, Pedro, N. Ortego, José Luis Pérez Castrillón, et al.. (2021). Multiple vertebral fractures after suspension of denosumab. A series of 56 cases. International Journal of Clinical Practice. 75(10). e14550–e14550. 5 indexed citations
3.
Gracia-Tello, Borja, Carmen Pilar Simeón‐Aznar, Vicent Fonollosa, et al.. (2021). POS1408 REPRODUCIBILITY OF A NEW AUTOMATIC SYSTEM (CAPILLARY.IO) IN THE ANALYSIS OF NAILFOLD CAPILLAROSCOPY IMAGES. Annals of the Rheumatic Diseases. 80. 987–987.
4.
Gracia-Tello, Borja, Carmen Pilar Simeón‐Aznar, Vicent Fonollosa, et al.. (2021). POS0256 AUTOMATED CAPILLARY DETECTION AND IMAGE ANALYSIS SOFTWARE IN CAPILLAROSCOPY: CAPILLARY.IO. Annals of the Rheumatic Diseases. 80. 350–351.
5.
Espinosa, Gerard, Alfredo Castillo, Carlos Tolosa, et al.. (2020). SAT0316 ANTI-PM/SCL ANTIBODIES IN SYSTEMIC SCLEROSIS: CLINICAL ASSOCIATIONS IN THE RESCLE COHORT. Annals of the Rheumatic Diseases. 79. 1103–1104. 1 indexed citations
6.
García, José Alberto, et al.. (2019). THU0121 CIRCULATING FIBROBLAST GROWTH FACTOR-23 IS ASSOCIATED WITH DYSLIPIDEMIA IN RHEUMATOID ARTHRITIS PATIENTS. Annals of the Rheumatic Diseases. 78. 332–333. 1 indexed citations
7.
García, José Alberto, et al.. (2019). AB0294 THE EFFECT OF SMOKING ON ENDOTHELIN-1 IN PATIENTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 78. 1607–1607. 3 indexed citations
8.
Prieto-Peña, D., Monica Calderón-Goercke, V. Calvo-Río, et al.. (2019). THU0581 BIOLOGICAL THERAPY IN NON ISCHAEMIC OPTIC NEURITIS ASSOCIATED TO IMMUNE-MEDIATED INFLAMMATORY DISEASES. MULTICENTER STUDY. Annals of the Rheumatic Diseases. 78. 581–582.
9.
Loricera, J., Ricardo Blanco, José L. Hernández, et al.. (2016). Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review.. PubMed. 34(3 Suppl 97). S44–53. 36 indexed citations
10.
Perra, Daniela, Marco A. Alba, José Luís Callejas-Rubio, et al.. (2012). Adalimumab for the treatment of Behcet's disease: experience in 19 patients. Lara D. Veeken. 51(10). 1825–1831. 62 indexed citations
11.
Díaz-Llopis, M., David Salom, Miguel Cordero‐Coma, et al.. (2012). Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients. Ophthalmology. 119(8). 1575–1581. 173 indexed citations
12.
Loricera, J., V. Calvo-Río, M. Díaz-Llopis, et al.. (2012). FRI0329 Adalimumab therapy in 40 patients with refractory juvenile idiopathic arthritis-associated uveitis. A multicenter study. Annals of the Rheumatic Diseases. 71. 425–425. 1 indexed citations
13.
Ramos‐Casals, Manuel, Francisco José García Hernández, José Luís Callejas-Rubio, et al.. (2010). Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.. PubMed. 28(4). 468–76. 102 indexed citations
14.
Callejas-Rubio, José Luís, Javier Oliver, Javier Martı́n, & N. Ortego. (2006). Anakinra in mutation-negative CINCA syndrome. Clinical Rheumatology. 26(4). 576–577. 9 indexed citations
15.
López‐Nevot, Miguel Ángel, José Mario Sabio, Laura Paco, et al.. (2004). Systemic lupus erythematosus in southern Spain: a comparative clinical and genetic study between Caucasian and Gypsy patients. Lupus. 13(12). 934–940. 20 indexed citations
16.
Callejas-Rubio, José Luís, et al.. (1998). [Arterial hypertension secondary to renal infarction in primary antiphospholipid syndrome].. PubMed. 111(5). 199–199.
17.
Callejas-Rubio, José Luís, et al.. (1998). Recurrent epididymo-orchitis secondary to Behçets disease.. PubMed. 160(2). 496–496. 6 indexed citations
18.
Ortego, N., et al.. (1998). Celiac Disease Presenting as Chronic Anemia Associated With Heart Block. The American Journal of Gastroenterology. 93(8). 1391–1392. 10 indexed citations
19.
Ortego, N., Bruce L. Miller, Ismaël Mena, & Barton W. Palmer. (1995). SPECT in Neurosyphilis. Clinical Nuclear Medicine. 20(3). 272–272. 2 indexed citations
20.
Ortego, N., et al.. (1992). Cyclic Neutropenia: A Cause of Recurrent Aphthous Stomatitis Not to Be Missed. Dermatology. 184(3). 205–207. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Frigui Breakdown of academic impact, for papers by A. Hamzaoui Breakdown of academic impact, for papers by Esen Kasapoğlu Günal Breakdown of academic impact, for papers by M. Khanfir Breakdown of academic impact, for papers by Ayten Yazıcı Breakdown of academic impact, for papers by A Sbaï Breakdown of academic impact, for papers by Hanns-Martin Lorenz Breakdown of academic impact, for papers by Olcay Aydıntuğ Breakdown of academic impact, for papers by V. Calvo-Río Breakdown of academic impact, for papers by Adam Adler
Rankless by CCL
2026